• br Perspective AA LA and other PUFAs and

  2025-01-23

  

  Perspective AA, LA and other PUFAs and their lipid metabolites play an important role in human diseases. 12/15-LOX which is the metabolic enzyme of them plays an important role in the pathogenesis-related diseases such as atherosclerosis, diabetic nephropathy, neurological diseases and other path

• br Current therapies for metabolic diseases Inborn errors

  2025-01-23

  

  Current therapies for metabolic diseases Inborn errors of metabolism caused by deficiency of particular enzymes due to loss of function mutations or deletions have been treated by decreasing the intake of the enzymatic substrate, supplementation with an essential cofactor or vitamin, increasing m

• br Materials and methods br

  2025-01-22

  

  Materials and methods Results The average body weights for each group of mice over the course of the study are shown in Fig. 2A. The average body weights of the mice in the saline control group and PACAP group increased slightly during the study. In contrast, starting at day 17, the body weigh

• Based on our previous work

  2025-01-22

  

  Based on our previous work [13] and the observation that SNX9 is a partner for ACK, we have investigated interactions involving the SH3 domain of SNX9, and identified for the first time synaptojanin-1 as an alternate partner. This SH3 domain can bind a single site in ACK1, but multiple sites in the

• Although ACE genetic variance does not

  2025-01-22

  

  Although ACE genetic variance does not influence the level of bradykinin significantly, the bradykinin level tends to be affected by ACE inhibitor therapy used by patients. ACE inhibitor reduces the ACE activity that may lead to the accumulation of serum bradykinin. The level of bradykinin tends to

• Although ACE genetic variance does not

  2025-01-22

  

  Although ACE genetic variance does not influence the level of bradykinin significantly, the bradykinin level tends to be affected by ACE inhibitor therapy used by patients. ACE inhibitor reduces the ACE activity that may lead to the accumulation of serum bradykinin. The level of bradykinin tends to

• Illustrated in is the protocol we applied

  2025-01-22

  

  Illustrated in is the protocol we applied for the screens of novel furoic acids as ACL inhibitors. We constructed our furan carboxylate library that contained 1446 2-furoic PF-06463922 derivatives and 501 3-furoic acid derivatives by performing substructural searches of the ZINC database. We limi

• MPC 6827 hydrochloride br Conclusions A large body of eviden

  2025-01-22

  

  Conclusions A large body of evidence indicates that oxidative stress is involved in the pathogenesis of NDDs. Hence, reducing oxidative stress or suppressing its downstream pathways may be beneficial for the treatment of these diseases, especially such chronic diseases as AD or glaucoma. Here we

• br Experimental section br Results

  2025-01-21

  

  Experimental section Results and discussion Conclusion Acknowledgement This work was supported by the National Natural Science Foundation of China (Grant Nos. 81401489), the Shanghai Pujiang Program (17PJ1402800) and the Shanghai Sailing Program (Grant No. 14YF1409000). Introduction

• Consideration of the rate of product

  2025-01-21

  

  Consideration of the rate of product formation at different substrate concentrations and estimation of Michaelis-Menten parameters gives some insight into the possible mechanisms underlying the observed decreases in enzyme activity. Estimates based on two-substrate concentrations lack precision and

• In past Zebra fish Danio rerio has emerged as a

  2025-01-21

  

  In past, Zebra fish (Danio rerio) has emerged as a suitable model for early vertebrate development, and a number of targeted mutations in the zebrafish genome led to phenotypic alterations that resemble human diseases [34]. A 12-LOX in Zebra fish has been cloned and knock down of this zf12-LOX enzym

• Kif15-IN-2 Another possible scenario is that the same

  2025-01-21

  

  Another possible scenario is that the same pathologic process has different effects in different people. It might be that the pathway outlined in Fig. 6A is operative in some individuals, but other individuals have a factor Q (which could be genetic or environmental) that blocks the effect of A on T

• br Conclusion br Introduction Lung

  2025-01-21

  

  Conclusion Introduction Lung cancer is the principal cause of death by cancer and the third most common cancer worldwide (Sorber et al., 2016). Lung cancer has two main types: small cell carcinomas (approximately 20%) and non-small cell lung cancers (NSCLC) (about 80%) (Fan et al., 2016). NSC

• br Transparency document br Introduction G

  2025-01-21

  

  Transparency document Introduction G protein-coupled receptors (GPCRs) comprise a diverse family of seven transmembrane domain-containing receptors represented by over 800 genes in humans. GPCRs respond to a range of stimuli, including peptides, hormones, growth factors, lipids, odorants, and

• The central problem in amnesia developing following

  2025-01-21

  

  The central problem in amnesia developing following impairment of long-term memory consolidation or reconsolidation is a question of the underlying mechanisms, whether it is caused by impairment of retrieval or memory storage mechanisms [3,8,9,[15], [16], [17], [18]]. To answer this question, severa

16051 records 21/1071 page Previous Next First page 上5页 2122232425 下5页 Last page